Jan. 29, 2003 — Protiveris Inc., a Maryland-based developer of bioMEMS technology for protein research and drug discovery, has developed a prototype of a biosensor system capable of detecting multiple biomolecular interactions in drug research and development.
The VeriScan 3000, which monitors the movement of microcantilevers by focusing tiny laser beams on the microcantilevers’ free ends, offers real-time, simultaneous detection. Protiveris said it plans to place the system in product trials with leading bio-pharmaceutical companies, according to a news release.